СПИСОК ЛИТЕРАТУРЫ

1. Баранов В.С. Геномика на пути к предиктивной медицине // Acta

Nature. – 2009. – №3. – 77-86 c.

2. Выборнова И. В. Определение чувствительности Candida spp. к флуконазолу двумя вариантами диско-диффузионного метода / И.

3. Диагностика микозов/ Р. А. Аравийский, Н. В. Васильева, Н. Н.

Климко // СПб.: Издательский дом СПбМАПО, 2004. – 186 с., ил

4. Диагностика и лечение микозов в отделениях реанимации и интенсивной терапии. Российские национальные рекомендации. / А.Б. Бакиров, А. В. Веселов, А. В. Власенко и др. (под ред. Климко Н. Н.) // Москва: Изд.дом «Компания Боргес», 2010 г. – 92 с.

4. Идентификация возбудителей микозов с помощью секвенирования ДНК / Ю. В. Михайлова, М. В. Руднева, Г. А. Чилина и др. // Проблемы медицинской микологии. – 2013. – Т. 15, №2. – С. 105-106.

5. Микологические культуральные исследования. Методические рекомендации / Н. В. Васильева, Н. П. Елинов, Т. С. Богомолова и др.

// ГБОУ ВПО СЗГМУ им. И.И.Мечникова. – СПб. – 2013 г. – 40с.

6. Михайлова Ю.В. Молекулярная идентификация представителей Aspergillus spp. из Российской Коллекции Патогенных Грибов / Ю. В. Михайлова, Г. А. Чилина, А. Г. Полищук // Проблемы медицинской микологии. – 2012. – Т. 14, №4. – С. 46-49.

7. Мухитов А.Р., Архипова С.С. Никольский Е.Е. Современная световая микроскопия в биологических и медицинских исследованиях. М.: Наука, 2011.-140с.

8. Патогенные и условно-патогенные макро- и микромицеты как объекты царства грибов (Fungi), их характеристика с учётом требований международного кодекса ботанической номенклатуры:

учебное пособие, выпуск I. / Н.П. Елинов, Н. В. Васильева, А. А. Маметьева и др. (под ред. Елинова Н. П. // СПб.:КОСТА, 2011. – 64 с.

9. Пестова, Л.А. Кандидемия и острый диссеминированный кандидоз у больных в отделениях интенсивной терапии: дис.

03.00.24, 14.00.37 / Пестова Любовь Альбертовна. – СПб, 2004. – 160 с.

10. ПЦР в реальном времени /Ребриков Д.В., Саматов Г.А., Трофимов Д.Ю. и др. (под ред. Д.В. Ребрикова). // М.: БИНОМ. Лаборатория знаний. – 2014. - 223 с.

11. Рациональная научно-практическая терминология патогенных и условно-патогенных грибов и вызываемых ими заболеваний: учебное пособие, выпуск III. / Н. П. Елинов, Н. В. Васильева, Е. Р. Рауш и др. (под ред. Елинова Н. П. // СПб.:ООО «МГК», 2014. – 72 c.

12. Реброва, О.В. Статистический анализ медицинских данных.

Применение пакета прикладных программ «Статистика» / О.В. Реброва – 3-е изд. – Москва: Медиа Сфера, 2006. – 312 с.

13. СП 1.3.2322-08. Безопасность работы с микроорганизмами III и IV групп патогенности (опасности) и возбудителями паразитарных болезней. – М., Российская газета, 2011. – 13 июля .

14. Candida. Кандидозы. Лабораторная диагностика / под ред. Н. П.

Елинов, Н. В. Васильева, А. А. Степанова и др. ( под ред. Елинова

Н.П.) // СПб.: КОСТА, 2010. – 224 с.

15. In vitro активность флуконазола и вориконазола в отношении более

10000 штаммов дрожжей: результаты 5-летнего проспективного исследования ARTEMIS Disk в России / А. В. Веселов, Н. Н. Климко, О. И. Кречикова и др. // Клиническая микробиология и антимикробная химиотерапия. – 2008. – Т. 10.,№ 4. – С. 345-354.

16. A 1-year prospective survey of candidemia in Italy and changing epidemiology over one decade / A. M. Tortorano, A. Prigitano, C. Lazzarini et al. // Infection. – 2013. – Vol.41. – P.655–662.

analysis (1894-1996)/ Kluwer Academic Publishers, the Netherlands, 2003

18. Alastruey-Izquierdo A. Antifungal susceptibility profile of cryptic species of Aspergillus. / A. Alastruey-Izquierdo, L.Alcazar-Fuoli, M.Cuenca- Estrella // Mycopathologia. – 2014. – Vol.178. – P.427–433.

19. Amino acid substitutions in the Candida albicans sterol Δ5,6-desaturase (Erg3p) confer azole resistance: characterization of two novel mutants with impaired virulence / F.

20. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics / White T. J., Bruns T., Lee S. et al. // PCR Protocols: A Guide to Methods and Applications. – 1990. – P. 315-322.

21. An Implementation Strategy for the Use of Chromogenic Media in the Rapid, Presumptive Identification of Candida Species / H. J. Adam, S.E. Richardson, M. Roscoe et al. // The Open Mycology Journal. – 2010. – Vol.4. – P. 33-38.

22. Antifungal susceptibility of 205 Candida spp. isolated primarily during invasive Candidiasis and comparison of the Vitek 2 system with the CLSI broth microdilution and Etest methods / N. Bourgeois, L. Dehandschoewercker, S. Bertout et al. // J. Clin. Microbiol. – 2010. – Vol.48. – P.154-161.

23. Antifungal susceptibility testing: current role from the clinical laboratory perspective / B. Posteraro, R. Torelli, E. De Carolis // Mediterr. J. Hematol. Infect. Dis. – 2014. – Vol.6. – e2014030.

24. Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance / M. Xiao, X. Fan, S. C. Chen et al. // J. Antimicrob. Chemother. – 2014. – Vol.3.

– P. 152-161

isolates culture collection / R. Lima-Neto, C. Santos, N. Lima et al. // Braz. J. Microbiol. – 2014. – Vol.45. – P. 515–522.

26. Arendrup M. Epidemiology of invasive candidiasis / M. Arendrup // Current

Opinion in Critical Care. – 2010. – Vol.16. – P. 445–452.

27. Assesment of ribosomal Large-Subunit D1-D2, Internal Transcribed Spacer

1, and Internal Transcribed Spacer 2 regions as targets for molecular identification of medically important Aspergillus species / H. P. Hinrikson, S. F. Hurst, T. J. Lott et al. // J. Clin. Microbiol . – 2007. – Vol. 43, № 5. – P.

2092-2103.

28. ATB fungus Comparative evaluation of ATB Fungus 2 and Sensititre YeastOne panels for testing in vitro Candida antifungal susceptibility / E.

29. Atlas of clinical fungi: electronic version 3.1. [Electronic resource] / Hoog

G.S. de, Guarro J., Gene J. et al. - Utrecht, Reus, 2011. – (СD-ROM).

30. AUXACOLOR2. User manual book. BioRad – USA. – 2003. – 79 p.

31. Balashov S. V. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1 / S. V. Balashov, S. Park, D. S. Perlin // Antimicrob. Agents Chemother. – 2006. – Vol.50. – P. 2058-2063.

32. Barnett J. A. A history of research on yeasts 12: medical yeasts part 1,

Candida albicans / J. A. Barnett // Yeast. – 2008. – Vol.25. – P.385–417.

33. Candida bloodstream infections: comparison of species distributions and antifungal resistance patterns in community-onset and nosocomial isolates in the SENTRY Antimicrobial Surveillance Program, 2008-2009 / M. A Pfaller, G. J. Moet, S. A. Messer et al. // Antimicrobial Agents and Chemotherapy. – 2011. –Vol. 55. – P. 561-566.

34. Candida bracarensis detected among isolates of Candida glabrata by peptide nucleic acid fluorescence in situ hybridization: susceptibility data

Magill et al. // J. Clin. Microbiol. – 2008. – Vol.46. – P. 443–446.

35. Candida identification: a journey from conventional to molecular methods in medical mycology / M. Z. Alam, Q. Alam, A. Jiman-Fatani et al. // World J. Microbiol. Biotechnol. – 2014. – Vol. 30. – P. 1437-1451.

36. Candida guilliermondii, an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program / M. A. Pfaller, D. J. Diekema, M. Mendez et al. // J. Clin. Microbiol. – 2006. – Vol.44. – P.3551–3556.

37. Candidiasis: New Insights for the Healthcare Professional / Q. Ashton

Acton (eds.) – Scholarly Editions, Atlanta, 2013. – P.57

38. Candida parapsilosis sensu stricto and the closely related species Candida orthopsilosis and Candida metapsilosis in vulvovaginal candidiasis / Y.

39. Candida parapsilosis,Candida orthopsilosis, and Candida metapsilosis virulence in the non-conventional host Galleria mellonella / S. Gago, R. Garcнa-Rodas, I.Cuesta et al. // Virulence. – 2014. – Vol. 5 - P.278–285.

40. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6- year prospective candidaemia survey from the fungal infection network of Switzerland / C. Orasch, O. Marchetti, J. Garbino et al. // Clin. Microbiol. and Infect. – 2014. – Vol.20. – P. 698–705.

41. Candidemia in Europe: epidemiology and resistance. / A. M. Tortorano, C.

Kibbler, J. Peman et al. // Int J Antimicrob Agents. – 2006. – Vol.27. –

P.359–366.

42. Candidemia at intensive care units (ICU) in Saint-Petersburg, Russia / L.

Pestova, N. Klimko, T. Bogomolova et al. // Clinical microbiology and infection. – 2004. – Vol. 10. – P. 639-640.

teaching hospital complex / A. Lopes Motta, G. Madeira, D. de Almeida et al. // Braz. J. Infect. Dis. – 2010. – Vol.14. – P.15-24.

44. Candidaemia associated with decreased in vitro fluconazole susceptibility: is Candida speciation predictive of the susceptibility pattern? / D. A. Oxman, J.K. Chow, G.Frendl et al. // J. Antimicrob. Chemother. – 2010. – Vol.65. – P.1460-1465.

45. Clinical and Laboratory Standards Institute (CLSI). Reference method for antifungal disk diffusion susceptibility testing of yeasts; approved guideline

// CLSI document M44-A. – 2004. – CLSI, Wayne, PA, USA.

46. Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: third edition // CLSI document M27-A3. – 2008. - CLSI, Wayne, PA, USA.

47. Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: third edition // CLSI document 3rd Informational Supplement M27-S3.

48. Clinical and Laboratory Standards Institute (CLSI). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: third edition // CLSI document 3rd Informational Supplement M27-S4. – 2012. - CLSI, Wayne, PA, USA.

49. Clinical and Laboratory Standards Institute (CLSI). Interpretive criteria for identification of bacteria and fungi by DNA target sequencing; approved guideline. // CLSI document MM18-A. – 2008. – CLSI, Wayne, PA, USA.

50. Clinically achievable caspofungin, micafungin and anidulafungin concentrations within the bloodstream:experience from a mycology reference laboratory /N. P. Wiederhold, , D. A. Sutton, A. W. Fothergill et al. // Mycoses. – 2013. – Vol. 56. –P. 58.

51. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America / P. G. Pappas, C. A.

535.

52. Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program / M. A. Pfaller, L. Boykena, R. J. Hollisa et al. // J. Clin. Microbiol. – 2009. – Vol.48. – P.1358–1365.

53. Comparison of minimal inhibitory concentration elevation in Candida dubliniensis and Candida albicans after fluconazole exposure in vitro / K. Chaicumpar, S. Srichangwang, K. Samerpitak et al. // Mycoses. – 2013. – Vol.56. – P.63.

54. Crist A.E. Jr. Comparison of the MUREX C. albicans, albicans-Sure, and BactiCard Candida test kits with the germ tube test for presumptive identification of Candida albicans / A.E.Jr. Crist, T.J. Dietz, K. Kampschroer // J. Clin. Microbiol. – 1996. – Vol. 34. – P. 2616–2618.

55. Cuenca-Estrella M. Antifungal drug resistance mechanisms in pathogenic fungi: from bench to bedside / M. Cuenca-Estrella // Clin. Microbiol. Infect.

– 2014. – Vol. 20, Suppl. 6. – P.54–59.

56. Direct MALDI-TOF Mass Spectrometry Assay of Blood Culture Broths for Rapid Identification of Candida Species Causing Bloodstream Infections: an Observational Study in Two Large Microbiology Laboratories / T. Spanu, B. Posteraro, B. Fiori et al. // J. Clin. Microbiol. – 2012. - Vol. 50. – P. 176-

179.

57. Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulence / A. Lohberger, A. T. Coste, D. Sanglard et al. // Eukaryot. Cell – 2014. – Vol.13. – P.127–142.

58. Delaloye J Invasive candidiasis as a cause of sepsis in the critically ill patient / Delaloye J, Calandra T // Virulence. – 2014. – Vol.5. – P.161-169.

leaf tissue / J. J. Doyle, J. L. Doyle // Phytochem. Bull. – 1987. – Vol.19. –

P. 11-15.

60. Doyle S. Fungal proteomics: from identifcation to function / S. Doyle // Jour. Federation of European Microbiological Societies. – 2011. – Vol.321.

– P.18-23.

61. Eksi F. In Vitro Susceptibility of Candida Species to Four Antifungal Agents Assessed by the Reference Broth Microdilution Method / F. Eksi, E. D. Gayyurhan, I. Balci // The Scientific World Journal – 2013. – Vol. 6 . – P.214-219.

62. Elucidating drug resistance in human fungal pathogens / J.L. Xie , E.J.

Polvi, T. Shekhar-Guturja // Future Microbiol. – 2014. – Vol.9. – P.523–

542.

63. ESCMID guideline for the diagnosis and management of Candida diseases

2012: diagnostic procedure / M. Cuenca-Estrella, P. E. Verweij, M. C. Arendrup et al. //Clinical Microbiology and Infection diseases. – 2012. – Vol.18.suppl. 7. – P.9-18.

64. Epidemiology of invasive fungal infections in the intensive care unit: Results of a multicenter Italian survey (AURORA Project) / M.T. Montagna, G. Caggiano, G. Lovero et al. // Infection. – 2013. – Vol.41. – P. 645–653.

65. Epidemiology and predictive factors for early and late mortality in Candida bloodstream infections: a population-based surveillance in Spain / M. Puig- Asensio, B. Padilla, J. Garnacho-Montero et al. // Clin Microbiol Infect. –

2014. – Vol.20. – O245-254.

66. Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance) registry, 2004–2008 / M. Pfaller, D. Diekema, H.-U. Meier-Kriesche et al. // Diagnostic Microbiology & Infectious Disease. – 2012. – Vol.74. – P.323–331.

67. Evaluation of New Colorimetric Vitek 2 Yeast Identification Card by Use of Different Source Media / G. Valenza, J. Strasen, F. Schäfer et al. // J. Clin. Microbiol. – 2008. – Vol.46. – P.3784-3787.

68. Evolution of Mating within the Candida parapsilosis Species Group / S.

Sixiang , L. M. Holland, C. F. McGee et al. // Eukaryot Cell. –2011. –

Vol.10. – P. 578–587.

69. Evolution of pathogenicity and sexual reproduction in eight Candida genomes / G. Butler, M. D. Rasmussen, M. F. Lin et al // Nature. – 2009. – Vol. 459. – P.657-662.

70. Espinel-Ingroff A.V. Medical Mycology in the United States. A historical analysis (1894-1996) / A.V. Espinel-Ingroff // Mycopathologia – 2005. – Vol/ 160/ - P. 187-188.

71. Espinel-Ingroff A. EUCAST and CLSI: Working Together Towards a Harmonized Method for Antifungal Susceptibility Testing / A. Espinel- Ingroff, M.Cuenca-Estrella, E. Canton // Clinical Microbiology and Infection. – 2013. – Vol.7. – p 59-67

72. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: A multicenter, prospective, observational study in France (2005–2006) / O. Leroy, J.-P. Gangneux et al. // Crit. Care Med. –

2009. – Vol.37. – P. 1612-1618.

73. Espinel-Ingroff A. International and multicenter comparison of EUCAST and CLSI M27-A2 broth microdilution methods for testing susceptibilities of Candida spp. to fluconazole, itraconazole, posaconazole, and voriconazole / A. Espinel-Ingroff, F. Barchiesi, M. Cuenca-Estrella // J. Clin. Microbiol. – 2005. – Vol.43. – P.3884-3889.

74. Espinel-Ingroff A. EUCAST and CLSI: Working Together Towards a Harmonized Method for Antifungal Susceptibility Testing / A. Espinel- Ingroff, M. Cuenca-Estrella, E. Cantуn // Clinical Microbiology and Infection. – 2013. – Vol.7. – P.59-67

75. European Committee for Antifungal Susceptibility Testing (EUCAST).

Method for the determination of broth dilution MICs of antifungal agents for fermentative yeasts // EUCAST definitive document EDef 7.1. – 2004. – EUCAST, Geneva.

76. Evaluation of VITEK 2 and RapID yeast plus systems for yeast species identification: experience at a large clinical microbiology laboratory. / M. Sanguinetti, Porta, M. Sali et al. // J. Clin. Microbiol. – 2007. – Vol.45. – P.1343–1346.

77. First report of a clinical isolate of Candida haemulonii in Brazil / J.Nobrega de Almeida, A. Lopes Motta, F. Rossi et al. // Clinics (Sao Paulo). – 2012. Vol.67. – P.1229–1231.

78. Fleck R. In vitro susceptibility of Candida species to five antifungal agents in a German university hospital assessed by the reference broth microdilution method and Etest. / R. Fleck, D. Annebärbel, H. Herbert // J. Antimicrob. Chemother. – 2007. – Vol.59. – P. 767–771.

79. FUNGEMYCA Study Group Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey / J. Peman, E. Canton, G. Quindos, et al. // Journal of Antimicrobial Chemotherapy. – 2012. – Vol. 67. – Suppl. 5. – P. 1181–

1187.

80. Genetic dissection of azole resistance mechanisms in Candida albicans and their validation in a mouse model of disseminated infection / D. M. MacCallum, A. Coste, F. Ischer et al. // Antimicrob. Agents Chemother. –

2010. – Vol. 54. – P.1476–1483.

81. Gundes S. G. Comparative performance of Fungichrom I, Candifast and API 20C Aux systems in the identification of clinically significant yeasts / S. G. Gundes, S. Gulenc, R. Bingol // J. Med. Microbiol. – 2011. – Vol. 50. – p.1105-1110.

candidemia / J. Guinea // Clin. Microbiol. and Infect. – 2014. – Vol.20, Suppl.6. – P.5–10.

83. Hameed S. Novel regulatory mechanisms of pathogenicity and virulence to combat MDR in Candida albicans / S. Hameed, Z. Fatima // Int. J. Microbiol. – 2013. - Vol.2013 – P.1-10.

84. Hidden Killers: Human Fungal Infections / G. D. Brown, D. W. Denning, A.

R. Gow et al. // Sci. Transl. Med. – 2012. – Vol. 4. – P.165

85. Improved clinical laboratory identification of human pathogenic yeasts by matrix-assisted laser desorption ionization time-of-flight mass spectrometry

/ O. Bader, M. Weig, L. Taverne-Ghadwal et al. // Clin Microbiol Infect. –

2011. – Vol.17. – P.1359-65.

86. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population- based active surveillance program / R. A. Hajjeh, A. N. Sofair, L. H. Harrison et al. // J. Clin. Microbiol. – 2004. – Vol.42. – P.1519–1527.

87. Invasive candidiasis in pediatric intensive care in Greece: a nationwide study / L. Vogiatzi, S. Ilia, G. Sideri et al. // Intensive Care Medicine. –

2013. – Vol. 39. – P. 2188 – 2195.

88. Invasive candidemia in Norway a comparison of 2 decades / L. Hesstvedt, P.

Gaustad, R. Hannula et al. // Mycoses. – 2013. – Vol.56. – 15.

89. Invasive infections due to Candida norvegensis and Candida inconspicua: report of 12 cases and review of the literature / J. Guitard, A. Agoulvant, V. Letscher-Bru et al. // Medical Mycology. – 2013. – Vol.51. – P.795-799.

90. Iwen P.C. Utilization of the internal transcribed spacer regions as molecular targets to detect and identify human fungal pathogens / P. C. Iwen, S. H. Hinrichs, M. E. Rupp // Med Mycol. – 2002. – Vol. 40. – P.87-109.

91. Jamal W. Y. Comparative evaluation of two matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS)

Ahmad // Intern. J. Infect. Dis. – 2014. – Vol.26. – P. 14-21.

92. Khardori N. Future of diagnostic microbiology / N. Khardori // Indian J Med Microbiol. – 2014. – Vol. 32. – P. 371-377.

93. Kofteridis D.P. Caspofungin-non-susceptible Candida isolates in cancer patients / D.P. Kofteridis, R. E. Lewis, D. P. Kontoyiannis // Journal of Antimicrobial Chemotherapy. – 2010. – Vol.65. – P. 293-295.

94. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance / A. J. Barnes // J. hosp.infect. – 2002. – Vol.50. – P.243-260.

95. Kurtzman C. P. Systematics and taxonomy of yeasts / C. P. Kurtzman // Contrib. Microbiol. – 2000. – Vol.51. – P.14.

96. Kwon-Chung K. J. Phylogenetic spectrum of fungi that are pathogenic to humans / K.J. Kwon-Chung // Clinical Infect. Dis. – 1996. – Vol.19. – P.1-7.

97. Lachance M.-A. Kluyveromyces van der Walt (1971)/ M.-A. Lachance, T.

Boekhout, J.W. Fell // The yeasts: a taxonomic study / C.P. Kurtzman, J.W.Fell, T. Boekhout (eds.) – Elsevier Science & Technology, Amsterdam,

2011. – Р. 477-479.

98. Laboratory biosafety manual. WHO. 3rd ed – Geneva, 2004. – 170 p.

99. Latin American Invasive Mycosis Network. Epidemiology of candidemia in Latin America: a laboratory-based survey / M. Nucci, F. Queiroz-Telles, T. Alvarado-Matute et al. // PLoS ONE. – 2013. – Vol.8. – e59373.

100. Li T. Y. Characterization of Aspergillus spores by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry / T. Y. Li, B. H. Liu, Y. C. Chen // Rapid Commun. Mass Spectrom. – 2000. – Vol.14. – P.2393–

2400.

101. Matrix-assisted laser desorption ionization-time of flight mass spectrometry for fast and reliable identification of clinical yeast isolates / G. Marklein, M. Josten, U. Klanke et al. // J. Clin. Microbiol. – 2009. – Vol.47. –P.2912-

2917.

102. Matrix-assisted ultraviolet-laser desorption of nonvolatile compounds / M.

Karas, D. Bachmann, D. Bahr et al. //Int. J. Mass Spectrom. Ion Proc. –

1987. – Vol. 78. – P. 53-68.

103. MALDI Biotyper 3.1. User manual revision 1. Bruker Daltonics. – Bremen.

– 2012. – 212 p.

104. MALDI-TOF MS: an upcoming tool for rapid detection of antibiotic resistance in microorganisms / M. Kostrzewa, K. Sparbier, T. Maier et al. // Prot. Clin. Appl. – 2013. –Vol.7. – P.767–778.

105. McIlroy, M. A. Failure of fluconazole to suppress fungemia in a patient with fever, neutropenia, and typhilitis / M. A. McIlroy // J. Infect. Dis. –

1991. – Vol.163. – P.420–421.

106. MFS multidrug transporters in pathogenic fungi: do they have real clinical impact? / C. Costa, P. J. Dias, I. Sa-Correia et al. // Front. Physiol. – 2014. – Vol. 5. – P.197.

107. Mnichowska-Polanowska M. In vitro susceptibility testing of candida albicans by using Micronaut-Am method / M. Mnichowska-Polanowska // Mycoses – 2013. - Vol. 56. – P.68.

108. Multicenter Evaluation of the New VITEK 2 Advanced Colorimetric Yeast Identification Card / D. J. Hata, L. Hall, A.W. Fothergill et al. // J Clin Microbiol. – 2007. – Vol. 45. – P.1087–1092.

109. Multicenter Comparison of the Vitek 2 Antifungal Susceptibility Test with the CLSI Broth Microdilution Reference Method for Testing Caspofungin, Micafungin, and Posaconazole against Candida spp. / J. F. Peterson, M. A. Pfaller, D. J. Diekema et al. // J. Clin. Microbiol. – 2011. – Vol.49. – P.1765–1771.

110. Messer S.A. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003) / S. A. Messer, R. N. Jones, T.R. Fritsche // J. Clin. Microbiol. – 2006. – Vol.44. – P.1782-1787.

111. Metabolic control of antifungal drug resistance / N. Robbins , C. Collins , J.

Morhayim et al. // Fungal Genet. Biol. – 2010. – Vol. 47. – P.81–93.

112. Molecular Identification and Antifungal Susceptibility Testing of Clinical Isolates of the Candida rugosa Species Complex and Proposal of the New Species Candida neorugosa / K. Paredes, A. Deanna, J. Sutton et al. //J. Clin. Microbiol. – 2012. – Vol. 50. – P. 2397-2403.

113. Molecular Identification and Antifungal Susceptibility of Yeast Isolates Causing Fungemia Collected in a Population-Based Study in Spain in 2010 and 2011/ J. Guinea, O. Zaragoza, P. Escribano et al. // Antimicrob Agents Chemother. – 2013. – Vol.58. – P. 1529-1537.

114. Moran G, Coleman D, Sullivan D. An introduction to the medically important Candida Species / R. A. Calderone, C. J. Clancy // Candida and Candidiasis / R. A. Calderone, C. J. Clancy. (eds). – ASM Press, Washington, DC, 2002. – P. 11- 27.

115. National surveillance of fungemia in Denmark (2004 to 2009) / M. C.

Arendrup, B. Bruun, J. J. Christensen et al. // J Clin Microbiol. – 2011. –

Vol.49. – P.325–334.

116. No increase in primary nosocomial candidemia in 682 German intensive care units during 2006 to 2011/ E. Meyer, C. Geffers, P. Gastmeier et al. // Euro Surveill. – 2013. – Vol.18. – P.10-12.

117. Odds F. C. One year prospective survey of Candida bloodstream infections in Scotland / F. C. Odds, M. F. Hanson, A. D. Davidson // J. Med. Microbiol.

– 2007. – Vol.56. – P. 1066–1075.

118. Page B. T. Rapid identification of Candida species and other clinically important yeast species by flow cytometry / B. T. Page, C. P. Kurtzman // J. Clin. Microbiol. – 2005. – Vol.43. – P.4507-4514.

119. Pappas P. G. Antifungal Clinical Trials and Guidelines: What We Know and Do Not Know / P. G. Pappas // Cold Spring Harbor Perspectives in medicine. – 2014. – Vol.12. – P. 15-21

120. Pappas PG. Clinical practice guidelines for the management of candidiasis:

2009 update by the Infectious Diseases Society of America / Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr // Clinical Infection Diseases. –

2009. – Vol.48. – P.503-535.

121. PCR protocol for specific identification of Candida nivariensis, a recently described pathogenic yeast / J. Alcoba-Florez , M. del Pilar, F.J. A. Gonzalez-Paredes et al. // J. Clin. Microbiol. – 2005. – Vol.43. – P. 6194–

6196.

122. Perlin D.S. Antifungal drug resistance: do molecular methods provide a way forward? / D. S. Perlin // Curr. Opin. Infect. Dis. – 2009. – Vol.22. – P.568–

573.

123. Perlroth J. Nosocomial fungal infections: epidemiology, diagnosis, and treatment / J. Perlrot, B. Choi, B. Spellberg // Medical Mycology. – 2007. – Vol.45. – P. 321-346.

124. Pestova L. Candidemia at intensive care units (ICU) in Saint-Petersburg, Russia / Pestova L., Klimko N., Bogomolova T. et al. // Clinical microbiology and infection. – 2004. – Vol. 10. – P.639-640.

125. Pfaller M.A. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment / M. A. Pfaller // Am. J. Med. – 2012. – Vol.125. – S3–S13.

126. Pfaller M. A. Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 Systemically active antifungal agents when tested against Candida spp. / M. A. Pfaller, M. Castanheira // Diagnostic Microbiology and Infectious Disease. – 2014. – Vol.79. –P.198–

204.

127. Pfaller M. A. Triazole and Echinocandin MIC Distributions with Epidemiological Cutoff Values for Differentiation of Wild-Type Strains from Non-Wild-Type Strains of Six Uncommon Species of Candida / M. A. Pfaller, M. Castanheira, D. J. Diekema // J. Clin. Microbiol. – 2011. – Vol.49. – P. 3800–3804.

128. Pfaller M. A. Epidemiology of Invasive Candidiasis: a Persistent Public

Health Problem / M. A. Pfaller,D. J. Diekema // Clin. Microbiol. Rev. –

2007. – Vol.20. – P.133–163.

129. Pfaller M. A. Candida guilliermondii, an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program / M. A. Pfaller, D. J. Diekema, M. Mendez // J.Clin.Microbiol. – 2006. – Vol. 44. – P.3551–3556.

130. Population structure and properties of Candida albicans, as determined by multilocus sequence typing / A. Tavanti, A.D. Davidson, M.J. Fordyce et al.

// J. Clin. Microbiol. – 2005. – Vol. 43. – P.5601–5613.

131. Prevalence of Candida bracarensis and Candida nivariensis in a Spanish collection of yeasts: comparison of results from a reference centre and from a population-based surveillance study of candidemia / M. Cuenca-Estrella, A. Gomez-Lopez, G. Isla et al. // Med Mycol. – 2011. –Vol. 49. – P.525-

529.

132. Protein and polymer analyses up to m⁄z 100000 by laser ionization time-of- flight mass-spectrometry / K. Tanaka, H. Waki, Y. Ido et al. // Rapid Commun. Mass Spectrom. – 1988. – Vol. 2. – P. 151-153.

133. Qiao-Ting C. Comparison of the Accuracy of Two Conventional Phenotypic Methods and Two MALDI-TOF MS Systems with That of DNA Sequencing Analysis for Correctly Identifying Clinically Encountered Yeasts / C. Qiao-Ting, L.Tai-Fen, T. Shih-Hua // J Clin Microbiol. – 2014.

– Vol.60. – P. 3225–3235.

134. Quantitation of Candida CFU in Initial Positive Blood Cultures

/Christopher D. Pfeiffer, Gregory P. Samsa et al. // Journal of Clinical

Microbiology. – 2011. – Vol.49, p.2879–2883.

135. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a

6.5-Year Analysis of Susceptibilities of Candida and Other Yeast Species to

Fluconazole and Voriconazole by Standardized Disk Diffusion Testing / M.

A. Pfaller, D. J. Diekema, M. G. Rinaldi et al. //J. Clin. Microbiol. – 2005. –

Vol.43. – P.5848–5859.

136. Raju S.B. Isolation and Identification of Candida from the Oral Cavity / S.

B. Raju, Rajappa S. // International Scholarly Research Notices. – 2011. –

Vol. 201. – P. 1-8.

137. Rapid Emergence of Echinocandin Resistance during Candida kefyr

Fungemia Treatment with Caspofungin / A. Fekkar, I. Meyer, J. Y. Brossas

// Antimicrob. Agents Chemother. – 2013. – Vol.57. – P.2380–2382.

138. Rapid antifungal susceptibility testing by matrix-assisted laser desorption ionization-time of flight mass spectrometry analysis / A. Vella, E. De Carolis, L. Vaccaro et al. / J. Clin. Microbiol. – 2013. – Vol.51. – P. 2964–

2969.

139. Rapid identification and susceptibility testing of Candida spp. from positive blood cultures by combination of direct MALDI-TOF mass spectrometry and direct inoculation of Vitek 2 / E. A. Idelevich, C. M. Grunewald, J. Wüllenweber et al. // (2014) PLoS ONE 9: e114834].

140. Recommendations for the diagnosis of candidemia in Latin America / A.

Lopes Colombo, J. A. Cortes J. Zurita et al. // Revista Iberoamericana de

Micologia. – 2013. – Vol. 30. – P.150–157.

141. Reiss E., Shadomy H.J., Lyon G.M. Fundamental medical mycology. –

2011. – 624p.

142. Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? / D. Maubon, C. Garnaud, T. Calandra et al. // Intensive Care Med. –

2014. – Vol.40. – P.1241–1255.

143. Results from the ARTEMIS DISK Global Antifungal Surveillance Study,

1997 to 2007: a 10.5-Year Analysis of Susceptibilities of Candida Species to Fluconazole and Voriconazole as Determined by CLSI Standardized Disk Diffusion / M.A. Pfaller, D.J. Diekema, D. L. Gibbs et al. // J Clin Microbiol. – 2010. – Vol.48. – P. 1366–1377.

144. Risk prediction for invasive candidiasis / A. Ahmed, A. Azim, A. K.

Baronia et al. // Indian Journal of Critical Care Medicine. – 2014. - Vol. 18, P. 682-688.

145. Sanglard D. Antifungal drug resistance mechanisms in fungal pathogens from the perspective of transcriptional gene regulation / D. Sanglard, A. Coste, S. Ferrari // FEMS Yeast Res. – 2009. – Vol. 9. – P.1029–1050

146. Screening for amino acid substitutions in the Candida albicans Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature / F. Morio, C. Loge, B. Besse et al. // Diagn. Microbiol. Infect. Dis. – 2010. – Vol. 66. – P.373–384.

147. Seminational Surveillance of Fungemia in Denmark: Notably High Rates of Fungemia and Numbers of Isolates with Reduced Azole Susceptibility / M. C. Arendrup, K. Fuursted, B.Gahrn-Hansen et al. // J. Clin. Microbiol. –

2005. – Vol.43. – P. 4434-4440.

148. Species distribution and antifungal resistance profiles among Candida spp. isolated from bloodstream infections in a Belgian university hospital / I. Montesinos, A. Cardentey-Reyes, M.Dodemont et al. // Mycoses. – 2013. Vol.56. – P.21.

149. Species identification and antifungal susceptibility of Candida bloodstream isolates from population-based surveillance in two US cities: 2008-2011 / S. R. Lockhart, N. Iqbal, A. M. Ahlquist et al. // J. Clin. Microbiol. – 2012. – Vol.50. – P.3435–3442.

150. Species distribution and susceptibility profile of Candida species in a Brazilian public tertiary hospital / A. Bruder, N.,Carlos, H. Camargo et al. // BMC Research Notes. – 2010. – Vol.3. - P. 514-518.

151. Species distribution and susceptibility profile of Candida species in a Brazilian public tertiary hospital / A Bruder-Nascimento, CH Camargo, MF Sugizaki et al.// BCM Res Notes. – 2010. – Vol.3. – P.1-5.

152. Shawn R. Lockhart Lodderomyces elongisporus Masquerading as Candida parapsilosis as a Cause of Bloodstream Infections / S. R. Lockhart, M. A.

Pfaller, D.J. Diekema // Journal of Clinical Microbiology. – 2008. – Vol.46.

– P.1374–1376.

153. Sudbery P. The distinct morphogenic states of Candida albicans / P.

Sudbery, N. Gow, J. Berman // Trends in Microbiology. – 2004. – Vol.12. –

P.317- 324.

154. St-Germain G. Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005 / G. St-Germain, M. Laverdière, R. Pelletier // Infection Diseases and Medical Microbiology. – 2008. – Vol.19. - P. 55–62.

155. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance / A. S. Kao, M. E. Brandt, W. R. Pruitt et al. // Clin. Infect. Dis. – 1999. – Vol.29. – P.1164–1170.

156. The changing epidemiology of healthcare-associated candidemia over three decades / D. Diekema, S. Arbefeville, L. Boyken et al. // Diagn Microbiol Infect Dis. – 2012. – Vol.73. – P.45–48.

157. The ROCANET study: preliminary results from anprospective observational survey of candidaemia in the Rome city / M. Sanguinetti, N. Petrosillo, B. Posteraro et al. // Mycoses – 2013. - Vol. 56. – P.101.

158. Use of the VITEK 2 system to identify and test the antifungal susceptibility of clinically relevant yeast species / M.S.C. Melhem, A. Bertoletti, H.R.L. Lucca et al. // Braz. J. Microbiol. – 2013. – Vol.44. – P.1257-1266.

159. Variation in Candida spp. distribution and antifungal resistance rates among bloodstream infection isolates by patient age: report from the SENTRY Antimicrobial Surveillance Program (2008-2009) / M. A. Pfaller, M. Castanheira, S. A. Messer et al. // Diagn. Microbiol. Infect. Dis. – 2010. – Vol. 68. – P. 278–283.

160. Variacion de la epidemiologia de las fungemias y de la sensibilidad a fluconazol de los aislamientos en los ultimos 10 años en España: resultados del estudio FUNGEMYCA. J. Peman, E. Canton, M. J. Linares-Sicilia et al.

// Rev. Iberoam. Micol. – 2011. – Vol.28. – P.91–99.

161. van Veen S. Q. High-Throughput Identification of Bacteria and Yeast by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry in Conventional Medical Microbiology Laboratories / S. Q. van Veen, E. C. J. Claas, E. J. Kuijper // J Clin Microbiol. – 2010. – Vol.48.

– P. 900–907.

162. Variation in Susceptibility of Bloodstream Isolates of Candida glabrata to Fluconazole According to Patient Age and Geographic Location in the United States in 2001 to 2007 / M. A. Pfaller, S. A. Messer, R. J. Hollis et al.

// J Clin Microbiol. – 2009. – Vol.47. – P. 3185–3190.

163. Yapar N. Epidemiology and risk factors for invasive candidiasis / N.

Yapar// Ther. Clin. Risk Manag. – 2014. – Vol.10. – P.95–105.

Работы по теме диссертации:

164. Видовая идентификация возбудителей инвазивного кандидоза методом MALDI-TOF масс-спектрометрии / Е.Р. Рауш, Ю.В. Михайлова, Н.В. Васильева и др. // Фундаментальные исследования в современной медицине: достижения и перспективы. Сборник материалов 1-ой отчетной сессии научных подразделений СЗГМУ им. И.И.Мечникова.- СПб.,2013. – С.25-26.

165. Идентификация Candida spp. с помощью MALDI-TOF масс- спектрометрии / Е.Р. Рауш, Н.В. Васильева, Е.В. Шагдилеева и др. // Проблемы медицинской микологии. – 2013. – Т 15, №2. – С. 115-116.

166. Инвазивный кандидоз на отделениях реанимации и интенсивной терапии Ленинградской областной клинической больницы / Е.Р. Рауш, Е.В. Шагдилеева, Н.В. Васильева и др. // Проблемы медицинской микологии. – 2014. – Т 16, №2. – С. 147

167. Определение в и д о в возбудителей инвазивного кандидоза: в поиске быстрых решений / Е.Р. Рауш, Н.В. Васильева, Н.Н. Климко и др.

// Проблемы медицинской микологии. – 2013. – Т 15, №4. – С. 87-91.

168. Случай успешного лечения микст-микоза – инвазивного кандидоза (кандидемии) и инвазивного аспергиллеза (легких, придаточных пазух и мягких тканей носа) у пациента с неходжкинской лимфомой / Е.Р. Рауш, Е.В. Шагдилеева, С.Н. Хостелиди и др. // Проблемы медицинской микологии. – 2013. – Т 15, №1. – С. 22-28.

169. Определение чувствительности возбудителей инвазивного кандидоза к противогрибковым препаратам методами CLSI M27-A3 и CLSI M44-A

/ Е.Р. Рауш, Т.С. Богомолова, Н.В. Васильева и др. // Фундаментальные исследования в современной медицине: достижения и перспективы. Сборник материалов 1-ой отчетной сессии научных подразделений СЗГМУ им. И.И.Мечникова.- СПб., 2013. – С.24-25.

170. Определение чувствительности возбудителей инвазивного кандидоза к флуконазолу и вориконазолу по международным стандартам / Е.Р. Рауш, Н.В. Васильева, Т.С. Богомолова и др. // Проблемы медицинской микологии. – 2013. – Т 15, №1. – С. 60-63.

171. Первое описание случая успешного лечения микотического менингита, обусловленного Candida albicans и Trichosporon asahii / Е.В. Шагдилеева, Е.Р. Рауш, Н.В. Васильева и др. // Проблемы медицинской микологии. – 2013. – Т 15, №2. – С. 138-139

172. Случай успешного лечения микст-микоза, обусловленного Candida krusei и Aspergillus flavus / Е.Р. Рауш, Е.В. Шагдилеева, С.Н. Хостелиди и др. // Сборник научных трудов Всероссийской конференции с международным участием Пятые научные чтения, посвященные памяти член-корр. РАМН, з.д.н. РФ, профессора О.К. Хмельницкого "Современные подходы в клинико- морфологической диагностике и лечении заболеваний человека". - 2013. - C. 374-375.

173. Случай успешного лечения рецидивирующего диссеминированного кандидоза с поражением ободочной кишки и легких у пациентки, получающей хронический гемодиализ / Е.В. Шагдилеева, Е.Р. Рауш,

Т.С. Богомолова и др. // Научное издание «Успехи медицинской микологии». - 2014. - Т. XIII. – Гл. 11. - С. 280-281.

174. Случаи микст-микозов (инвазивных кандидоза и аспергиллеза) у гематологических больных / Е.Р. Рауш, Е.В. Шагдилеева, Т.С. Богомолова и др. // Проблемы медицинской микологии. – 2014. – Т 16,

№2. – С. 147-148.

175. Случай успешного лечения микотического перитонита (возбудитель – Candida albicans) у пациентки с острым панкреонекрозом / Е.Р. Рауш, Е.В. Шагдилеева, Т.С. Богомолова и др. // Проблемы медицинской микологии. – 2014. - T. 16. - № 2. - С. 131-132.

176. Случай успешного лечения кандидозного перитонита (возбудитель- Candida albicans) у пациентки с острым панкреонекрозом / Е.Р. Рауш, С.Н. Хостелиди, Е.В. Шагдилеева и др. // Проблемы медицинской микологии. – 2014. – Т 16, №3. – С. 26-31.

177. Успешное лечение сочетанного микоза - инвазивного кандидоза и инвазивного аспергиллеза у пациента с неходжкинской лимфомой / Е.Р. Рауш, Е.В. Шагдилеева , С.Н. Хостелиди и др. // Сборник материалов 86-ой конференции « Мечниковские чтения-2013» (г. Санкт- Петербург, 23 апреля 2013 г.).- Санкт-Петербург, 2013. – С.94-

95

178. Antifungal susceptibility profiles of pathogens of invasive candidiasis in Russia / E. Raush, N. Vasilyeva, E.Shagdileeva et al. // Final Program European Congress of Clinical Microbiology and Infectious Diseases (Barcelona, Spain, 10-13 May 2014) – P.103

179. Combination of invasive candidiasis and invasive aspergillosis in hematological patients / E. R.Raush, S. N. Khostelidi, T. S. Bogomolova et al. // Final Programm and Abstracts 12th ASM Conference on Candida and Candidiasis (New Orleans, Louisiana, USA, 26-30 March 2014) –P.107

180. Combination of invasive aspergollosis and invasive candidiasis in hematological / E.Raush, S.Khostelidi, T. Bogomolova et al. // 6th advances against aspergillosis. - 2014. - P. 164.

181. Identification of the etiologic agents of invasive candidosis by matrix- assisted laser desorption/ionisationtime of flight mass spectrometry (MALDI-TOF MS) / N.V. Vasilyeva, E.R. Raush, S.V. Sidorenko et al. // Final Programm European Congress of Clinical Microbiology and Infectious Diseases (Berlin, Germany, 29 April 2013) – P.148

182. Invasive candidiasis in intensive care units of the tertiary hospital in St.

Petersburg, Russia./ E. R. Raush, E. V. Shagdileeva, N.V. Vasilyeva et al. // Final Programm and Abstracts 12th ASM Conference on Candida and Candidiasis (New Orleans, Louisiana, USA, 26-30 March 2014) –P. 106-

107

183. Species distribution and antifungal susceptibility profiles among Candida spp. in Russia / E. Raush, N. Vasilyeva, E.Shagdileeva et al. // Final Programm and Abstracts 12th ASM Conference on Candida and Candidiasis (New Orleans, Louisiana, USA, 26-30 March 2014) – P. 87

184. Susceptibility testing of invasive candidosis pathogens to fluconazole by CLSI M27-A3 method / E. Raush, N.V.Vasilyeva, E.Shagdileeva et al. // Mycoses.- 2013.-Volume 56, Supplement 3.-P.109

185. Successful treatment of combination of invasive candidiasis (C. krusei) and aspergillosis (A. flavus) in haematological patient / E.R. Raush, E.Shagdileeva, T.S.Bogomolova et al. // Mycoses.- 2013.-Volume 56, Supplement 3.- P.116